drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous gene-modified CAR T-cell therapy co-transduced to express dual chimeric antigen receptors targeting CD19 and BCMA; upon antigen binding, activates T-cell cytotoxicity and cytokine release to kill malignant B cells and plasmablastic/plasma-cell–like components.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells co-transduced to express dual CARs targeting CD19 and BCMA. Antigen binding triggers CAR signaling (CD3zeta with costimulation), activating T-cell cytotoxicity and cytokine release to kill CD19+/BCMA+ malignant B cells and plasmablastic/plasma-cell–like components, with dual targeting designed to reduce antigen escape.
drug_name
ARI0003
nct_id_drug_ref
NCT06097455